Magnetic Resonance - Technology Information Portal Welcome to MRI Technology••
Info
  Sheets


Out-
      side
 



 
 'MultiHance' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'MultiHance' found in 1 term [] and 8 definitions []
1 - 5 (of 9)     next
Result Pages : [1]  [2]
Searchterm 'MultiHance' was also found in the following service: 
spacer
News  (2)  
 
MultiHance®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
MultiHance® is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (MRI) of the liver and central nervous system. MultiHance® is a small molecular weight chelate, which tightly binds the Gd atom. The substance is excreted partly by the kidneys, partly by the biliary system, which is especially unique.
MultiHance® is indicated, for the detection of focal liver lesions in patients with known or suspected primary liver cancer (e.g. hepatocellular carcinoma) or metastatic disease.
MultiHance® is also indicated in brain MRI and spine MRI where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced MRI.
Gd-BOPTA-enhanced MRA can provide superior vascular signal intensity and SNR, as compared with Gd-DTPA, due to its higher relaxivity, even at lower doses.
1 ml of solution MultiHance® contains: (0.5M) gadobenate dimeglumine 529 mg = gadobenic acid 334 mg + meglumine 195 mg. Viscosity at 37°C: 5.3 mPa
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.


Drug Information and Specification
NAME OF COMPOUND Gadobenate dimeglumine, Gd-BOPTA, E7155
DEVELOPER Bracco
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, predominantly positive enhancement
RELAXIVITY r1=9.7, r2=12.5, B0=0.5 T
PHARMACOKINETIC Extracellular, hepatobiliary
OSMOLALITY 1970 mosm/kg
CONCENTRATION 334 mg/ml
DOSAGE 0.05 mmol/kg for Liver MRI
0.1 mmol/kg for CNS MRI
PREPARATION Solution for injection
INDICATION CNS, Liver MRI
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Vials of 5, 10, 15 and 20 mL, 50 and 100 mL Multipacks (Pharmacy Bulk Package)
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU MultiHance® for sale Bracco Diagnostics
USA MultiHance® for sale Bracco Diagnostics
Australia MultiHance® for sale Bracco Pty Ltd
Japan E7155 Bracco-Eisai Co., Ltd.

spacer
 
• Share the entry 'MultiHance®':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'MultiHance®' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
MultiHance Package Insert(.pdf)
   by www.fda.gov    
  News & More:
FDA Expands Pediatric Age Range for MultiHance Contrast Agent
Tuesday, 30 January 2018   by www.empr.com    
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
BRACCO DIAGNOSTICS' MULTIHANCE EARNS FDA APPROVAL
Wednesday, 24 November 2004   by salesandmarketingnetwork.com    
MRI Resources 
Universities - Stent - Veterinary MRI - Service and Support - MRI Accidents - Spectroscopy
 
B-19036InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Short name: B-19036, central moiety: Gd+
B19036/7 compared with E-7155, Gd-BOPTA, Gd-BOPTA/Dimeg are synonyms for the contrast agent MultiHance®, marketed by Bracco Diagnostics Inc, Milan, Italy. B-19036 is a gadolinium chelate. See also the contrast agent info sheet about classifications, characteristics, etc.
spacer
 
Further Reading:
  News & More:
FDA Expands Pediatric Age Range for MultiHance Contrast Agent
Tuesday, 30 January 2018   by www.empr.com    
MRI Resources 
Journals - MR Myelography - Patient Information - RIS - MRI Training Courses - Research Labs
 
Bracco Diagnostics, Inc.MRI Resource Directory:
 - Manufacturers -
 
www.bdi.bracco.com

The company is a member of the Bracco Group, a highly innovative healthcare group and world leader in global integrated solutions for the diagnostic medical imaging field. The Bracco Group is headquartered in Milan, Italy. Its North American operations consist of Bracco Diagnostics and Bracco Research USA, both located in Princeton, New Jersey. Bracco Diagnostics is one of the fastest growing developers and marketers of diagnostic pharmaceuticals in North America, with products for various imaging applications, including Isovue® (iopamidol - X-ray contrast agent), ProHance® (gadoteridol - MRI contrast agent), SonoVue® (ultrasound contrast agent) and nuclear medicine products.
Gadoteridol has been available in Europe and the USA for several years. Holder of the Marketing Authorization: Bracco International B.V. - Strawinskylaan 3051 - 1077 ZX Amsterdam The Netherlands. (Contact: Kirk Deeter, Phone: +NL-303-838-8708)


Product Information
TRADE NAME
(LOCAL DISTRIBUTION)
FOR SALE FOR SALE /
DEVELOPMENT
DEVELOPMENT
MultiHance®
ProHance®
LumenHance®
B22956

Contact Information
Please see Bracco Diagnostics, Inc.'s Offices and Representations(Worldwide)
ONLINE www.bdi.bracco.com

spacer

• View the DATABASE results for 'Bracco Diagnostics, Inc.' (2).Open this link in a new window

 
Further Reading:
  News & More:
FDA Expands Pediatric Age Range for MultiHance Contrast Agent
Tuesday, 30 January 2018   by www.empr.com    
BRACCO DIAGNOSTICS' MULTIHANCE EARNS FDA APPROVAL
Wednesday, 24 November 2004   by salesandmarketingnetwork.com    
Searchterm 'MultiHance' was also found in the following service: 
spacer
News  (2)  
 
Bracco-Eisai Co., Ltd.MRI Resource Directory:
 - Manufacturers -
 
Eisai Co., Ltd. (Tokyo, Japan, President: Haruo Naito) and Bracco-Eisai Co., Ltd. (Tokyo, Japan, President: Toshio Matsumoto) decided to withdraw the new drug application (NDA) of E7155 (gadobenate meglumine), since new indications are emerging for the product and additional clinical data was necessary to complete the targeting product competitive risk/benefit profile. The product is currently marketed in other countries, and both companies are discussing a future development plan in Japan.

Product Information
TRADE NAME
(LOCAL DISTRIBUTION)
FOR SALE FOR SALE /
DEVELOPMENT
DEVELOPMENT
MultiHance®
ProHance®

Contact Information
MAIL Bracco Eisai Co., Ltd.
2-6, Kohinata 4-chome, Bunkyo-ku, Tokyo, 112-0006
PHONE +03-3817-3939

spacer

• View the DATABASE results for 'Bracco-Eisai Co., Ltd.' (2).Open this link in a new window

MRI Resources 
Resources - Stimulator pool - Liver Imaging - Equipment - Claustrophobia - Bioinformatics
 
Gadobenate DimeglumineInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Gd-BOPTA, generic name: Gadobenate dimeglumine
A paramagnetic MRI contrast agent (small molecular weight Gd-chelate) with 0.5 and 0.25 molar concentration.
The albumin-mediated relaxation enhancement may result in advantages for Gd-BOPTA over Gd-DTPA and other gadolinium agents in poorly vascularized, small, or lesions with low enhancement and in tumors with high concentrations of albumin. The substance is excreted partly by the kidneys (75-90%), partly by the biliary system (10-25%). The uptake in the liver is about 5% in humans. It is bolus injectable.
See Contrast Agents and MultiHance®.

spacer

• View the DATABASE results for 'Gadobenate Dimeglumine' (5).Open this link in a new window


• View the NEWS results for 'Gadobenate Dimeglumine' (1).Open this link in a new window.
 
Further Reading:
  Basics:
MultiHance Package Insert(.pdf)
   by www.fda.gov    
  News & More:
PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorisations
Friday, 10 March 2017   by www.satprnews.com    
MRI Resources 
MRI Training Courses - Lung Imaging - Functional MRI - Claustrophobia - Homepages - Universities
 
     1 - 5 (of 9)     next
Result Pages : [1]  [2]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



The impact of TTIP/TPP on the MRI scanner market will bring :
more variety 
better scanners 
more risk 
less regulation 
cheaper scanners 
Lost in Translation 
no change at all 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • 
Copyright © 2003 - 2018 SoftWays. All rights reserved. [ 18 March 2019]
Terms of Use | Privacy Policy | Advertising
 [last update: 2018-03-08 05:11:00]